SANOFI news, videos and press releases - Page 9
For more news please use our advanced search feature.
SANOFI - More news...
SANOFI - More news...
- Sanofi and Regeneron announce intent to restructure Antibody collaboration for Kevzara® (sarilumab) and Praluent® (alirocumab)
- Sanofi CEO unveils new strategy to drive innovation and growth
- Sanofi : Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion
- Sanofi : Positive results in Phase 3 trial for Toujeo® in children and adolescents with type 1 diabetes
- Sanofi Q3 well on track
- Sanofi announces settlement agreement related to Contingent Value Rights (CVRs) Litigation
- Sanofi : Dupixent® (dupilumab) now approved in European Union for severe chronic rhinosinusitis with nasal polyposis
- Sanofi: information concerning the total number of voting rights and shares, September 2019
- Sanofi : New England Journal of Medicine publishes data showing improved survival with Jevtana® (cabazitaxel) over second androgen receptor-targeted agent in metastatic castration-resistant prostate cancer
- Sanofi: information concerning the total number of voting rights and shares, August 2019
- Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9
- Sanofi: information concerning the total number of voting rights and shares, July 2019
- Sanofi : Online Availability of Sanofi Group’s Half-Year Financial Report for 2019
- Sanofi : Sanofi provides update on ZynquistaTM (sotagliflozin) type 2 diabetes Phase 3 program and collaboration with Lexicon
- Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care
- Sanofi: information concerning the total number of voting rights and shares, June 2019
- Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union
- Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
- Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma
- Soliqua® Phase 3 results significantly lowered blood sugar levels compared to GLP-1 receptor agonist treatments
- Paul Hudson to succeed Olivier Brandicourt as Chief Executive Officer
- Phase 3 trial of isatuximab combination therapy showed 40% reduction in the risk of disease progression or death for patients with relapsed/refractory multiple myeloma
- Information concerning the total number of voting rights and shares
- Sanofi : Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
- Sanofi: Annual General Meeting of April 30, 2019
- Sanofi: FDA approves Praluent® (alirocumab) to prevent heart attack, stroke and unstable angina requiring hospitalization
- ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes
- CHMP issues positive opinion for Libtayo® (cemiplimab) in advanced cutaneous squamous cell carcinoma
- Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER
- Information concerning the total number of voting rights and shares
